162 related articles for article (PubMed ID: 21604070)
21. Regulation of IL-21 signaling by suppressor of cytokine signaling-1 (SOCS1) in CD8(+) T lymphocytes.
Gagnon J; Ramanathan S; Leblanc C; Ilangumaran S
Cell Signal; 2007 Apr; 19(4):806-16. PubMed ID: 17126530
[TBL] [Abstract][Full Text] [Related]
22. SOCS1 regulates CCR7 expression and migration of CD4+ T cells into peripheral tissues.
Yu CR; Mahdi RM; Liu X; Zhang A; Naka T; Kishimoto T; Egwuagu CE
J Immunol; 2008 Jul; 181(2):1190-8. PubMed ID: 18606672
[TBL] [Abstract][Full Text] [Related]
23. Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs.
Song S; Wang Y; Wang J; Lian W; Liu S; Zhang Z; Liu F; Wei L
Eur J Cancer; 2012 Sep; 48(14):2252-9. PubMed ID: 22230748
[TBL] [Abstract][Full Text] [Related]
24. Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy.
Medrano RF; Catani JP; Ribeiro AH; Tomaz SL; Merkel CA; Costanzi-Strauss E; Strauss BE
Cancer Immunol Immunother; 2016 Apr; 65(4):371-82. PubMed ID: 26887933
[TBL] [Abstract][Full Text] [Related]
25. Amplifying IFN-γ Signaling in Dendritic Cells by CD11c-Specific Loss of SOCS1 Increases Innate Immunity to Infection while Decreasing Adaptive Immunity.
Alice AF; Kramer G; Bambina S; Baird JR; Bahjat KS; Gough MJ; Crittenden MR
J Immunol; 2018 Jan; 200(1):177-185. PubMed ID: 29150567
[TBL] [Abstract][Full Text] [Related]
26. SOCS-1 protects against Chlamydia pneumoniae-induced lethal inflammation but hampers effective bacterial clearance.
Yang T; Stark P; Janik K; Wigzell H; Rottenberg ME
J Immunol; 2008 Mar; 180(6):4040-9. PubMed ID: 18322213
[TBL] [Abstract][Full Text] [Related]
27. Silencing of SOCS1 in macrophages suppresses tumor development by enhancing antitumor inflammation.
Hashimoto M; Ayada T; Kinjyo I; Hiwatashi K; Yoshida H; Okada Y; Kobayashi T; Yoshimura A
Cancer Sci; 2009 Apr; 100(4):730-6. PubMed ID: 19469017
[TBL] [Abstract][Full Text] [Related]
28. IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma.
Lesinski GB; Badgwell B; Zimmerer J; Crespin T; Hu Y; Abood G; Carson WE
J Immunol; 2004 Jun; 172(12):7368-76. PubMed ID: 15187113
[TBL] [Abstract][Full Text] [Related]
29. Generation of a tumor-specific systemic response after intratumoral injection of IL-12 and IL-18-loaded polylactic acid microspheres.
Sabel MS; Arora A; Su G; Griffith KA; Mathiowitz E; Reineke JJ; Chang AE
J Immunother; 2007; 30(8):808-16. PubMed ID: 18049332
[TBL] [Abstract][Full Text] [Related]
30. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
[TBL] [Abstract][Full Text] [Related]
31. Suppressor of cytokine signaling-1 regulates signaling in response to interleukin-2 and other gamma c-dependent cytokines in peripheral T cells.
Cornish AL; Chong MM; Davey GM; Darwiche R; Nicola NA; Hilton DJ; Kay TW; Starr R; Alexander WS
J Biol Chem; 2003 Jun; 278(25):22755-61. PubMed ID: 12665516
[TBL] [Abstract][Full Text] [Related]
32. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
33. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
Ribas A; Wargo JA; Comin-Anduix B; Sanetti S; Schumacher LY; McLean C; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS
J Immunol; 2004 Apr; 172(8):4762-9. PubMed ID: 15067052
[TBL] [Abstract][Full Text] [Related]
34. SOCS1 prevents potentially skin-reactive cytotoxic T lymphocytes from gaining the ability to cause inflammatory lesions.
Rodriguez GM; D'Urbano D; Bobbala D; Chen XL; Yeganeh M; Ramanathan S; Ilangumaran S
J Invest Dermatol; 2013 Aug; 133(8):2013-22. PubMed ID: 23443260
[TBL] [Abstract][Full Text] [Related]
35. Loss of interferon-induced Stat1 phosphorylation in activated T cells.
Van De Wiele CJ; Marino JH; Whetsell ME; Vo SS; Masengale RM; Teague TK
J Interferon Cytokine Res; 2004 Mar; 24(3):169-78. PubMed ID: 15035850
[TBL] [Abstract][Full Text] [Related]
36. Suppressor of cytokine signaling-1 regulates inflammatory bowel disease in which both IFNgamma and IL-4 are involved.
Chinen T; Kobayashi T; Ogata H; Takaesu G; Takaki H; Hashimoto M; Yagita H; Nawata H; Yoshimura A
Gastroenterology; 2006 Feb; 130(2):373-88. PubMed ID: 16472593
[TBL] [Abstract][Full Text] [Related]
37. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
38. Neutralization of interferon-gamma in neonatal SOCS1-/- mice prevents fatty degeneration of the liver but not subsequent fatal inflammatory disease.
Bullen DV; Darwiche R; Metcalf D; Handman E; Alexander WS
Immunology; 2001 Sep; 104(1):92-8. PubMed ID: 11576226
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response.
Pan J; Zhang M; Wang J; Wang Q; Xia D; Sun W; Zhang L; Yu H; Cao X
J Cancer Res Clin Oncol; 2005 Jul; 131(7):468-78. PubMed ID: 15711825
[TBL] [Abstract][Full Text] [Related]
40. Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist.
Waiboci LW; Ahmed CM; Mujtaba MG; Flowers LO; Martin JP; Haider MI; Johnson HM
J Immunol; 2007 Apr; 178(8):5058-68. PubMed ID: 17404288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
